<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 11pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 16pt"><B></B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 16pt"><B>UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 16pt Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION<BR>
</B></FONT><B><FONT STYLE="font-size: 12pt">Washington, D.C. 20549</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font: 16pt Times New Roman, Times, Serif"><B>FORM
8-K<BR>
<BR>
</B></FONT><B><FONT STYLE="font-size: 12pt">Current Report<BR>
<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0.25in; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><B>January
25, 2012 (January 25, 2012)<BR>
</B></FONT><FONT STYLE="font-size: 10pt">Date of Report (Date of earliest event reported)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font: 16pt Times New Roman, Times, Serif"><B>MEDGENICS,
INC.<BR>
</B></FONT><FONT STYLE="font-size: 10pt">(Exact name of registrant as specified in its charter)</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 12pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 12pt"><B>1-35112</B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 12pt"><B>98-0217544</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(State or other jurisdiction of<BR>
incorporation or organization)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(Commission File Number)</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center">(I.R.S. Employer<BR>
Identification No.)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>555 California
Street, Suite 365</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>San Francisco,
California 94104</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">(Address of principal executive offices,
zip code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><FONT STYLE="font: 12pt Times New Roman, Times, Serif"><B>(415)
568-2245<BR>
</B></FONT><FONT STYLE="font-size: 10pt">(Registrant&rsquo;s telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 12pt">Not Applicable</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0pt; text-indent: 22pt; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):<BR STYLE="mso-special-character: line-break">
&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%; text-align: center"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD STYLE="width: 96%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Wingdings 2">&#163;</FONT></TD>
    <TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 10; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 1in"><B>Item 8.01</B></TD>
<TD><B>Other Information.</B></TD></TR></TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">On January 25, 2012, Medgenics, Inc.
(the &ldquo;Company&rdquo;) issued a press release announcing that its Board of Directors has set the close of business on March
2, 2012 as the record date for stockholders entitled to receive notice of, and to vote at, the Company&rsquo;s 2012 Annual Meeting
of Stockholders, which is currently anticipated to be held on April 3, 2012 in New York, New York. Because the date of the 2012
Annual Meeting of Stockholders will occur more than 30 days before the anniversary of the Company&rsquo;s prior annual meeting
of stockholders (held on September 7, 2011), the Company has set new deadlines for the receipt of stockholder proposals and related
matters as outlined below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Company also announced that the deadline
for submitting stockholder proposals pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 has been set at February
24, 2012, which the Company believes is a reasonable time before it begins to print and send proxy materials.&nbsp;&nbsp;In order
for a stockholder proposal to be considered for inclusion in the proxy statement, it must be received by the Company on or prior
to the close of business on February 24, 2012 at its principal executive offices at 555 California Street, Suite 365, San Francisco,
California 94104.&nbsp;&nbsp;Furthermore, in order to be considered &ldquo;timely&rdquo; for the purposes of Rule&nbsp;14a-4(c)
under the Securities Exchange Act of 1934 (relating to the circumstances under which a proxy may confer discretionary authority
to vote on certain matters), notices of stockholder proposals or director nominations intended to be presented at the 2012 Annual
Meeting of Stockholders must also be received on or prior to the close of business on February 24, 2012 at the same address. These
notices and stockholder proposals should be sent to the attention of Eugene A. Bauer, M.D., Executive Chairman of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Stockholders should understand that proposals
must comply with all of the requirements of Rule 14a-8 under the Securities Exchange Act of 1934, if applicable, and any applicable
requirements of our bylaws and Delaware law, and may be omitted if not in compliance with all applicable requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">A copy of the press release dated January
25, 2012 is attached hereto as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"><B>Item 9.01 &#9;Financial Statements and
Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d)&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Exhibits. The following exhibit is furnished herewith:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-left: 0; border-collapse: collapse">
<TR STYLE="vertical-align: baseline">
    <TD STYLE="width: 12%; padding-right: 0; padding-left: 0; text-indent: 0; text-decoration: underline"><U>Exhibit No.</U></TD>
    <TD STYLE="width: 88%; padding-right: -0.2in; padding-left: 5.4pt; text-indent: 0in; text-decoration: underline"><U>Description</U></TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding-right: -0.2in; padding-left: 5.4pt; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="padding-right: -0.2in; padding-left: 5.4pt; text-indent: 0in">&nbsp;</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding-right: 0; padding-left: 0">99.1</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-indent: 0.7pt">Medgenics, Inc. Press Release dated January 25, 2012.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 10; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 50%">&nbsp;</TD><TD STYLE="text-align: right; width: 50%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding-top: 12pt; padding-right: -2.4pt">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="padding-top: 12pt; padding-right: -2.4pt">MEDGENICS, INC.</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="width: 60%; padding-top: 12pt; padding-right: -2.4pt">&nbsp;</TD>
    <TD STYLE="width: 3%; padding-top: 12pt; padding-right: -2.4pt">By:<U> </U></TD>
    <TD STYLE="width: 5%; padding-top: 12pt; padding-right: -2.4pt; border-bottom: Black 1pt solid">/s/</TD>
    <TD STYLE="width: 23%; padding-top: 12pt; padding-right: -2.4pt; border-bottom: Black 1pt solid">Phyllis K. Bellin</TD>
    <TD STYLE="width: 9%; padding-top: 12pt; padding-right: -2.4pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding-right: -2.15pt">&nbsp;</TD>
    <TD STYLE="padding-right: -2.15pt">&nbsp;</TD>
    <TD STYLE="padding-right: -2.15pt">Name:</TD>
    <TD COLSPAN="2" STYLE="padding-right: -2.15pt">Phyllis K. Bellin</TD></TR>
<TR STYLE="vertical-align: baseline">
    <TD STYLE="padding-right: -2.15pt">&nbsp;</TD>
    <TD STYLE="padding-right: -2.15pt">&nbsp;</TD>
    <TD STYLE="padding-right: -2.15pt">Title:</TD>
    <TD COLSPAN="2" STYLE="padding-right: -2.15pt">Vice President &ndash; Administration</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 0; text-align: justify">&nbsp;Date:&#9;January
25, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; margin-left: 0; text-indent: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 10; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "8-K", "sequence": "1", "filename": "v300338_8k.htm", "description": "CURRENT REPORT", "secsgml_size_bytes": 15236}]
{"company-data": {"conformed-name": "MEDGENICS, INC.", "cik": "0001138776", "assigned-sic": "2836", "irs-number": "980217544", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-35112", "film-number": "12544554"}, "business-address": {"street1": "TERADION BUSINESS PK.", "street2": "P.O. BOX 14", "city": "MISGAV", "state": "L3", "zip": "20179", "phone": "1-646-239-1690"}, "mail-address": {"street1": "TERADION BUSINESS PK.", "street2": "P.O. BOX 14", "city": "MISGAV", "state": "L3", "zip": "20179"}, "former-company": {"former-conformed-name": "MEDGENICS INC", "date-changed": "20010419"}}
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM
8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
January
25, 2012 (January 25, 2012)
Date of Report (Date of earliest event reported)
MEDGENICS,
INC.
(Exact name of registrant as specified in its charter)
Delaware
1-35112
98-0217544
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification No.)
555 California
Street, Suite 365
San Francisco,
California 94104
(Address of principal executive offices,
zip code)
(415)
568-2245
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01
Other Information.
On January 25, 2012, Medgenics, Inc.
(the "Company") issued a press release announcing that its Board of Directors has set the close of business on March
2, 2012 as the record date for stockholders entitled to receive notice of, and to vote at, the Company's 2012 Annual Meeting
of Stockholders, which is currently anticipated to be held on April 3, 2012 in New York, New York. Because the date of the 2012
Annual Meeting of Stockholders will occur more than 30 days before the anniversary of the Company's prior annual meeting
of stockholders (held on September 7, 2011), the Company has set new deadlines for the receipt of stockholder proposals and related
matters as outlined below.
The Company also announced that the deadline
for submitting stockholder proposals pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 has been set at February
24, 2012, which the Company believes is a reasonable time before it begins to print and send proxy materials.  In order
for a stockholder proposal to be considered for inclusion in the proxy statement, it must be received by the Company on or prior
to the close of business on February 24, 2012 at its principal executive offices at 555 California Street, Suite 365, San Francisco,
California 94104.  Furthermore, in order to be considered "timely" for the purposes of Rule 14a-4(c)
under the Securities Exchange Act of 1934 (relating to the circumstances under which a proxy may confer discretionary authority
to vote on certain matters), notices of stockholder proposals or director nominations intended to be presented at the 2012 Annual
Meeting of Stockholders must also be received on or prior to the close of business on February 24, 2012 at the same address. These
notices and stockholder proposals should be sent to the attention of Eugene A. Bauer, M.D., Executive Chairman of the Board.
Stockholders should understand that proposals
must comply with all of the requirements of Rule 14a-8 under the Securities Exchange Act of 1934, if applicable, and any applicable
requirements of our bylaws and Delaware law, and may be omitted if not in compliance with all applicable requirements.
A copy of the press release dated January
25, 2012 is attached hereto as Exhibit 99.1.
Item 9.01 	Financial Statements and
Exhibits.
(d)
Exhibits. The following exhibit is furnished herewith:
Exhibit No.
Description
99.1
Medgenics, Inc. Press Release dated January 25, 2012.
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
MEDGENICS, INC.
By:
/s/
Phyllis K. Bellin
Name:
Phyllis K. Bellin
Title:
Vice President – Administration
Date:	January
25, 2012